Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation Combined With Tislelizumab and Lenvatinib in Gastric Cancer Liver Metastasis
NCT05893056Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in gastric cancer (GC), sponsored by Fudan University. Started Jun 2023; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05893056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893056.